Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Current Drug Metabolism
|
September 28, 2017
Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function
Sandra Pisonero-Vaquero, Diego Luis Medina
Cells
|
May 14, 2020
TFEB Modulates p21/WAF1/CIP1 during the DNA Damage Response
Sandra Pisonero-Vaquero, Chiara Soldati, Marcella Cesana, et al.
Current Medicinal Chemistry
|
August 6, 2015
Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
Sandra Pisonero-Vaquero, Javier González-Gallego, Sonia Sánchez-Campos, et al.
NPJ Systems Biology and Applications
|
September 2, 2017
Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses
Francesco Sirci, Francesco Napolitano, Sandra Pisonero-Vaquero, et al.
Bioinformatics (Oxford, England)
|
December 14, 2017
gene2drug: a computational tool for pathway-based rational drug repositioning
Francesco Napolitano, Diego Carrella, Barbara Mandriani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
February 5, 2014
Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin
Sandra Pisonero-Vaquero, María V García-Mediavilla, Francisco Jorquera, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 30, 2012
Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication
María Victoria García-Mediavilla, Sandra Pisonero-Vaquero, Elena Lima-Cabello, et al.
Free Radical Biology & Medicine
|
November 29, 2016
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation
David Porras, Esther Nistal, Susana Martínez-Flórez, et al.
Molecular Pharmacology
|
January 11, 2015
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease
Marta Benet, Carla Guzmán, Sandra Pisonero-Vaquero, et al.
Biochimica Et Biophysica Acta
|
January 16, 2013
The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease
Carla Guzmán, Marta Benet, Sandra Pisonero-Vaquero, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Current Drug Metabolism
|
September 28, 2017
Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function
Sandra Pisonero-Vaquero, Diego Luis Medina
Cells
|
May 14, 2020
TFEB Modulates p21/WAF1/CIP1 during the DNA Damage Response
Sandra Pisonero-Vaquero, Chiara Soldati, Marcella Cesana, et al.
Current Medicinal Chemistry
|
August 6, 2015
Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
Sandra Pisonero-Vaquero, Javier González-Gallego, Sonia Sánchez-Campos, et al.
NPJ Systems Biology and Applications
|
September 2, 2017
Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses
Francesco Sirci, Francesco Napolitano, Sandra Pisonero-Vaquero, et al.
Bioinformatics (Oxford, England)
|
December 14, 2017
gene2drug: a computational tool for pathway-based rational drug repositioning
Francesco Napolitano, Diego Carrella, Barbara Mandriani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
February 5, 2014
Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin
Sandra Pisonero-Vaquero, María V García-Mediavilla, Francisco Jorquera, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 30, 2012
Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication
María Victoria García-Mediavilla, Sandra Pisonero-Vaquero, Elena Lima-Cabello, et al.
Free Radical Biology & Medicine
|
November 29, 2016
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation
David Porras, Esther Nistal, Susana Martínez-Flórez, et al.
Molecular Pharmacology
|
January 11, 2015
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease
Marta Benet, Carla Guzmán, Sandra Pisonero-Vaquero, et al.
Biochimica Et Biophysica Acta
|
January 16, 2013
The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease
Carla Guzmán, Marta Benet, Sandra Pisonero-Vaquero, et al.
Page
of 2